Milestones still hang
In June 2005, we entered into an acquisition agreement with Cephalon, Inc., or Cephalon, pursuant to which we divested the compound,
TRISENOX. Cephalon was subsequently acquired by Teva Pharmaceutical Industries Ltd., or Teva. Under this agreement, we have the right to receive up
to $100 million in payments upon achievement by Teva of specified sales and development milestones related to TRISENOX. To date, we have received
$60.0 million of such potential milestone payments as a result of having achieved certain sales milestones.
